Journey Medical expects $20.3M cash; reaffirms FY2024 revenue guidance $55-60M

Journey Medical Corp

2024-FY EPS reported -$0.72 revenue$56,134,000

Cash and cash equivalents expected to be $20.3 million as of December 31, 2024.
Reaffirms FY2024 guidance: net product revenue $55-60M, SG&A $39-42M, R&D $8-10M.
Hosts Feb 5, 2025 conference call to update commercial launch plan for Emrosi (minocycline HCl ER 40 mg).
Investor presentation (Exhibit 99.1) attached but specific slide content not disclosed in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.